St. Jude Medical (NYSE:STJ) said today that it plans to rejigger the way it reports its sales to better reflect its focus in managing the business, beginning this year.

Little Canada, Minn.-based St. Jude, which saw its share price slide today after missing forecasts for its 4th-quarter sales, said it’s focus is shifting to 5 key key areas: Heart failure; atrial fibrillation; neuromodulation; cardiovascular disease; and traditional cardiac rhythm management.

The heart failure segment covers bi-ventricular CRT pacemakers and ICDs, the ventricular assist devices acquired along with Thoratec last October, and the CardioMEMS implantable heart failure monitor St. Jude bought in June 2014. The traditional CRM segment covers the company’s single- and dual-chamber pacemakers and ICDs.

The atrial fibrillation unit adds left atrial appendage closure products to the AF products previously reported under that name, St. Jude said, while the neuromodulation division remains unchanged.

Finally, the cardiovascular disease unit covers the heart valve repair and replacement, structural heart defect, active vascular closure, compression-assist, pressure measurement guidewire, diagnostic coronary imaging, percutaneous catheter introducer, diagnostic guidewire, percutaneous heart pump, renal denervation and vascular plug categories, the company said.

Here’s a look at what the comparable sales would have been had the new divisions been in place last year:

STJ shares were off -6.2% to $55.51 apiece today in late-day trading.